Imagine facing the battle against a form of lung cancer so rare that it affects only about 2% of those diagnosed with non-small cell lung cancer (NSCLC). This is the reality for those with ROS1-positive NSCLC, a disease that could soon see transformative change with the approval of Nuvation Bio's
The pharmaceutical industry, often characterized by lengthy and costly drug development cycles, is on the brink of a revolutionary shift. A strategic partnership between IQVIA, a leader in clinical research services, and NVIDIA, a cutting-edge technology company renowned for AI innovations,
Amid growing public health challenges, the introduction of Generative Artificial Intelligence (GenAI) offers a transformative breakthrough in developing youth health campaigns aimed at issues like vaping. GenAI's efficiency has been spotlighted, showing the potential to drastically reduce the time
Chelonia Healthcare Limited has issued a recall for two specific batches of Paracetamol 500mg tablets upon the guidance of the Medicines and Healthcare Regulatory Authority (MHRA). This action arises from reports by healthcare professionals who identified discolored tablets in some of the packages.
In the rapidly evolving landscape of cancer treatments, Aumseqa (aumolertinib) has emerged as a promising advancement against non-small cell lung cancer (NSCLC) characterized by EGFR mutations. Recently approved by the Medicines and Healthcare products Regulatory Agency (MHRA), Aumseqa is
With a background steeped in biopharmaceutical innovation, Ivan Kairatov is a leading expert in oncology therapeutics. His insights into the development and approval of new cancer treatments are invaluable, especially regarding the European Commission's recent decision on AstraZeneca's Calquence
